Sutro Biopharma STRO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.52M-16.5% | $11.65M-21.4% | $9.69M+13.8% | $63.75M+148% | $17.4M+33.8% | ||
| $36.55M-29.2% | $36.64M-48.4% | $39.85M-35.8% | $38.33M-38.2% | $51.6M-9.3% | ||
| $7.58M-42.9% | $8.66M-4.1% | $8.74M-39.0% | $10.34M-16.4% | $13.27M+4.3% | ||
| $42K-99.8% | $4.39M— | $9.56M— | $18.42M— | $21.04M— | ||
| $44.18M-48.6% | $49.7M-37.9% | $58.15M-23.9% | $67.09M-9.8% | $85.91M+23.4% | ||
| $44.18M-48.6% | $49.7M-37.9% | $58.15M-23.9% | $67.09M-9.8% | $85.91M+23.4% | ||
| -$29.66M+56.7% | -$38.05M+41.7% | -$48.46M+28.7% | -$3.35M+93.1% | -$68.51M-21.1% | ||
| -204.2%+190pp | -326.7%+114pp | -499.9%+297pp | -5.2%+184pp | -393.8%+41.3pp | ||
| -$38.5M+49.3% | -$46.84M+33.2% | -$56.86M-16.5% | -$11.52M+76.0% | -$75.96M-30.5% | ||
| -$15K-314% | -$82K-103% | $0— | -$18K-325% | $7K— | ||
| -$38.48M+49.3% | -$46.76M+35.4% | -$56.86M-16.5% | -$11.5M+76.1% | -$75.97M-30.5% | ||
| -265%+172pp | -401.5%+87.7pp | -586.6%-14.0pp | -18%+169pp | -436.6%+10.9pp | ||
| -$2.94+67.6% | -$20.78+24.0% | -$0.67-13.6% | -$0.14+76.3% | -$9.08-1,439% | ||
| -$2.94+67.6% | -$20.78+24.0% | -$0.67-13.6% | -$0.14+76.3% | -$9.08-1,439% | ||
| 13.1M+56.4% | 8.5M+9.8% | 84.9M+3.4% | 84.6M+4.1% | 8.4M-86.4% | ||
| 13.1M+56.4% | 8.5M+9.8% | 84.9M+3.4% | 84.6M+4.1% | 8.4M-86.4% | ||
| -$1.01M+21.7% | -$782K-110% | -$737K-103% | -$1.04M+40.6% | -$1.29M+41.6% | ||
| $1.64M-48.7% | $1.53M-67.8% | $2.01M-58.8% | $2.52M-48.7% | $3.19M-22.1% | ||
| $9.47M+1.3% | $9.55M+9.9% | $9.67M+22.3% | $9.65M+32.4% | $9.34M+30.1% | ||
| $14.52M-16.5% | $11.65M-21.4% | $9.69M+13.8% | $63.75M+148% | $17.4M+33.8% | ||
| -$29.66M+56.7% | -$38.05M+41.7% | -$48.46M+28.7% | -$3.35M+93.1% | -$68.51M-21.1% | ||
| -$28.38M+57.4% | -$36.43M+42.5% | -$46.56M+29.6% | -$1.45M+96.9% | -$66.61M-21.5% | ||
| -$28.38M+57.4% | -$36.43M+42.5% | -$46.56M+29.6% | -$1.45M+96.9% | -$66.61M-21.5% | ||
| -195.4%+187pp | -312.7%+115pp | -480.3%+296pp | -2.3%+180pp | -382.9%+38.6pp | ||
| -$29.66M+56.7% | -$38.05M+41.7% | -$48.46M+28.7% | -$3.35M+93.1% | -$68.51M-21.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Sutro Biopharma's revenue?
- Sutro Biopharma (STRO) generated $99.6M in revenue over the trailing twelve months, up 49.9% year over year.
- Is Sutro Biopharma profitable?
- Sutro Biopharma is not currently profitable: it reported a net loss of $153.6M over the trailing twelve months, a -154.2% net margin.
- What is Sutro Biopharma's earnings per share?
- Sutro Biopharma's diluted EPS over the trailing twelve months is $-24.53.
- Where does Sutro Biopharma's income statement data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
